Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-02-28

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Radioimmunotherapy uses radiolabeled monoclonal antibodies to locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy may kill any tumor cells remaining after surgery.

PURPOSE: Phase II trial to study the effectiveness of combining intrathecal radioimmunotherapy and radiation therapy with combination chemotherapy in treating patients who have undergone surgery for medulloblastoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00099125

Brain and Central Nervous System Tumors

COMPLETED PHASE2

Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006916

Brain and Central Nervous System Tumors

TERMINATED PHASE2

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NCT05095376

Glioblastoma Gliosarcoma

RECRUITING PHASE3

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

NCT01644591

Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma +1 more

ACTIVE_NOT_RECRUITING PHASE2

Stereotactic Radiosurgery in Treating Patients With Brain Tumors

NCT00019578

Adult Central Nervous System Germ Cell Tumor Adult Malignant Meningioma Adult Medulloblastoma +11 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the feasibility of combining post-operative intrathecal radioimmunotherapy, craniospinal radiotherapy with intensity-modulated radiotherapy boost, and chemotherapy in patients with standard-risk medulloblastoma.
* Determine whether this regimen can maintain or exceed the current progression-free survival rate while decreasing long-term serious morbidity in these patients.
* Determine the long-term morbidities, most specifically neuropsychological, neuroendocrine, audiometric, and growth outcomes, in patients treated with this regimen.

OUTLINE:

* Radioimmunotherapy: Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 on days 1 and 8.
* Radiotherapy: Beginning as soon as possible after radioimmunotherapy, patients undergo external-beam and intensity-modulated radiotherapy 5 days a week for 6 weeks.
* Chemotherapy: Patients receive vincristine IV once weekly for 8 weeks concurrently with radiotherapy. Beginning about 6 weeks after completion of radiotherapy (4 weeks after vincristine), patients receive cisplatin IV over 6 hours and oral lomustine on day 0 and vincristine IV on days 0, 7, and 14. Treatment repeats every 6 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 6-20 patients will be accrued for this study within 3.2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain and Central Nervous System Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

histologic proof of medulloblastoma

Inclusion Criteria

* Patients must have histologic proof of medulloblastoma reviewed by the Department of Pathology at the Memorial Sloan-Kettering Cancer Center.
* Patients must begin study prescribed therapy within 42 days of neurosurgical resection of the tumor
* Age ≥ 3-years-old. Post-operative head MRI must confirm ≤ 1.5 cm2 of residual tumor is present.
* Head and spine MRI and lumbar CSF cytology must not show any definitive evidence of leptomeningeal dissemination (Chang stage M-0).
* Examinations evaluating extra-neural sites will not be mandated, but any performed for clinical indications must be free of metastatic disease.
* No prior RT or chemotherapy for the medulloblastoma is permitted Patients must have adequate CSF flow (defined as lack of compartmentalization) on an 111-Indium DTPA flow study.
* Patients must have adequate organ function as defined by:
* Hepatic: total bilirubin \< 2.0 mg/dl, AST \< 3 x the upper limit of normal.
* Renal: Calculated creatinine clearance or nuclear GFR ≥ 70 ml/min/1.73 m\^2.
* The patient, or for minors, a parent or legal guardian, must give informed written consent indicating they are aware of the investigational nature of this study.

Exclusion Criteria

* Unable to start study prescribed therapy within 42 days of neurosurgical resection of the tumor
* Age less than 3 years \> 1.5 cm2 residual tumor on post-operative head MRI
* Evidence of leptomeningeal dissemination on head or spine MRI or CSF cytology positivity
* Evidence of extra-neural metastases
* Prior radiation therapy or chemotherapy for the medulloblastoma
* Inadequate CSF flow on 111-Indium DTPA flow study Patients with signs or symptoms suggestive of increased intracranial pressure (headache, emesis, ocular paresis) will not be eligible until they are cleared by neurology and/or neurosurgery.
* Pregnancy
* Total bilirubin ≥ 2.0 mg/dl
* AST ≥ 3 x the upper limit of normal
* Creatinine clearance and GFR \< 70 ml/min/1.73 m\^2

Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No